NEPRINOL CLINICAL DATA

ENZYME	PUBLICATION	SUBJECTS	INTERVENTION	DURATION	ENDPOINTS	RESULTS
Neprinol	Evans et al 2016	9	3 capsules 3x daily	12 weeks	Blood viscosity and glucose tolerance	Neprinol demonstrated clinically significant reductions in blood viscosity as well as glucose tolerance. Additional testing is indicated for further expanation to impacts on blood viscosity.
Neprinol	Evans et al 2016	9	3 capsules 3x daily	12 weeks	Safety	No adverse events were reported during or after the study. All safety endpoints remained in the reference range throughout the study. This is significant considering Neprinol's impact on blood viscosity.
Nattokinase	Kim et al 2008	73	2,000 FU/day	8 weeks	Blood Pressure	After 8 weeks the patients given nattokinase showed imporvement versus their placebo counterparts. Study concluded that nattokinase supports healthy blood pressure.
Nattokinase	Hsia et al 2009	45	2x2,000 FU/day	8 weeks	Fibrinogen, Factor VII, Factor VIII	After 8 weeks, nattokinase had demonstrable effects on the blood factors and could therefore be considered as a safe and reliable supplement to support cardiovascular health.
Nattokinase	Pais et al 2006	in vitro	n/a	n/a	Blood Viscosity	In vitro testing of nattokinase on blood samples demonstrated a supportive effect for healthy red blood cell aggregation and blood viscosity.
Serrapeptase	Al-Khateeb et al 2008	24	10,000 SPU 3x daily	7 days	Swelling and pain intensity due to surgery	After 7 days, the patients given serrapeptase showed improvement versus their placebo counterparts. Study concluded that serrapeptase reduced swelling and pain after surgery vs placebo.
Serrapeptase	Esch et al 1989	66	not specified	3 days	Swelling and pain intensity due to injury	After 3 days, serrapeptase had demonstrable effects on the levels of swelling vs those in the placebo control group.



NEPRINOL CLINICAL DATA

ENZYME	PUBLICATION	SUBJECTS	INTERVENTION	DURATION	ENDPOINTS	RESULTS
Serrapeptase	Mazzone et al 1990	193	20,000 SPU 3x daily	7-8 days	Ear, nose and throat conditions	After 8 days, serrapeptase had demonstrable effects on the levels of pain and mucus secretion vs those in the placebo control group.
Serrapeptase	Tachibana et al 1984	174	20,000 SPU 3x daily	5 days	Swelling due to surgery	After 5 days, the patients given serrapeptase showed improvement versus their placebo counterparts. Study concluded that serrapeptase reduced swelling after surgery vs placebo.
Proteases	Bufod et al 2009	29	not specified	24 days	Strength, leukocyte activity, and inflammation after exertion	Testing demonstrated that protease supplementation attenuated muscle strenth losses after exercise by regulating leukocyte activity and inflammation.
Proteases	Miller et al 2004	20	325mg tablets 4x daily	4 days	Muscle recovery after exercise	Testing demonstrated that protease supplementation attenuated muscle injury from intense exercise and may facilitate muscle healing. The experimental group experienced diminished effects of delayed-onset muscle soreness vs placebo.
Bromelain	Klein et al 2000	73	not specified	3 weeks	Short-term pain of the knee	Testing indicated that the bromelain group had similar improvements to the NSAID group in the Lequesne Index, which indicates bromelain may be an effective option for pain.
Amla	Akthar et al 2011	32	1-3 grams per day	21 days	Blood glucose levels and cholesterol	Testing indicated that amla could improve blood glucose as well as support healthy lipd levels in the patient population. This study further supports why Neprinol may have had a clinically significant impact on blood glucose.

